New drug PLB-002 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. PLB-002 is designed to target a protein (Claudin 6) found on some…
Phase: PHASE1 • Sponsor: Primelink BioTherapeitics(ShenZhen) Limited • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC